Compare SYNX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | SNOA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.1M |
| IPO Year | 2024 | 2007 |
| Metric | SYNX | SNOA |
|---|---|---|
| Price | $1.17 | $3.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 209.8K | 26.0K |
| Earning Date | 02-23-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,003,000.00 | ★ $16,937,000.00 |
| Revenue This Year | $32.35 | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.02 |
| 52 Week Low | $0.73 | $1.75 |
| 52 Week High | $4.69 | $6.92 |
| Indicator | SYNX | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 59.73 |
| Support Level | $1.10 | $3.53 |
| Resistance Level | $1.29 | $3.89 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 83.98 | 81.57 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.